Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8950389 | 0.79 | PTGER4 (0.34) | POLBLMNA | |
| SCHEMBL8950506 | 0.72 | GAA (0.31) | L3MBTL1 | |
| SCHEMBL8950361 | 0.71 | LMNA (0.38) | POLBKMT2ALMNAL3MBTL1 | |
| SCHEMBL8950076 | 0.68 | FEN1 (0.46) | KMT2ALMNAL3MBTL1 | |
| SCHEMBL8950426 | 0.64 | TSHR (0.39) | POLBKMT2ALMNA | |
| SCHEMBL9058138 | 0.60 | CSNK2A2 (0.32) | — | |
| SCHEMBL8950606 | 0.59 | CA2 (0.36) | KMT2ALMNAL3MBTL1 | |
| SCHEMBL20487250 | 0.59 | MEN1 (0.39) | POLBKMT2AL3MBTL1 | |
| 1,4-Butanediol SCHEMBL2722579 | 0.58 | CYP4A11 (0.79) | CYP4A11CYP4F2POLBKMT2AL3MBTL1 | |
| SCHEMBL7514655 | 0.58 | CA12 (0.39) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5538966-A | ENZYME INHIBITORS FOR TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-07-23 | — | — | US | disclosed |